Literature DB >> 20406600

Management of neurocysticercosis.

Adolfo Ramírez-Zamora1, Tomás Alarcón.   

Abstract

BACKGROUND: Neurocysticercosis is a parasitic infection of the central nervous system caused by the larval stage of the tapeworm Taenia solium and is the most common parasitic infection involving the human nervous system. Neurocysticercosis represents one of the most common causes of symptomatic epilepsy in developing countries and is an increasing concern in industrialized nations.
METHODS: We conducted a review of the medical literature regarding the current management of neurocysticercosis in Latin American countries.
RESULTS: Mexico and Brazil report the highest incidence of neurocysticercosis in Latin America. However, major obstacles interfere with an accurate determination of the prevalence of neurocysticercosis, including the lack of standardized and comprehensive epidemiological systems, intrinsic limitations of current immunological studies, the high cost of neuroimaging studies in rural communities and the presence of asymptomatic patients with neuroimaging characteristic compatible with neurocysticercosis. As such, the real prevalence of the disease and its burden are likely underestimated in Latin America. There is no universal consensus or guidelines for the management of different forms of the disease, but most experts agree in the use of antihelminithic therapy when viable cysts are encountered and with the use of corticosteroids in patients presenting with encephalitis. DISCUSSION: Neurocysticercosis is a pleomorphic disease, with a broad spectrum of clinical and radiographic features. The medical management of neurocysticercosis is complex and needs to be individualized.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20406600     DOI: 10.1179/016164110X12644252260592

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  6 in total

1.  Cranial hypertrophic pachymeningitis secondary to neurocysticercosis.

Authors:  Thiago Cardoso Vale; Helena Duani; Daniela Lino Macedo; Paulo Pereira Christo
Journal:  Neurol Sci       Date:  2012-03-09       Impact factor: 3.307

2.  Quality of life in patients with neurocysticercosis in Mexico.

Authors:  Rachana Bhattarai; Christine M Budke; Hélène Carabin; Jefferson V Proaño; Jose Flores-Rivera; Teresa Corona; Linda D Cowan; Renata Ivanek; Karen F Snowden; Ana Flisser
Journal:  Am J Trop Med Hyg       Date:  2011-05       Impact factor: 2.345

Review 3.  Clinical manifestations, diagnosis, and treatment of neurocysticercosis.

Authors:  Julio Sotelo
Journal:  Curr Neurol Neurosci Rep       Date:  2011-12       Impact factor: 5.081

4.  Rare case of disseminated cysticercosis and taeniasis in a Japanese traveler after returning from India.

Authors:  Ken-ichiro Kobayashi; Fukumi Nakamura-Uchiyama; Takeshi Nishiguchi; Kenichi Isoda; Yasumasa Kokubo; Katsuhiko Ando; Masaki Katurahara; Yasuhito Sako; Tetsuya Yanagida; Akira Ito; Sentaro Iwabuchi; Kenji Ohnishi
Journal:  Am J Trop Med Hyg       Date:  2013-04-29       Impact factor: 2.345

5.  A dot-ELISA using a partially purified cathepsin-L-like protein fraction from Taenia solium cysticerci, for the diagnosis of human neurocysticercosis.

Authors:  R Piña; A H Gutiérrez; R H Gilman; D Rueda; C Sifuentes; M Flores; P Sheen; S Rodriguez; H H García; M Zimic
Journal:  Ann Trop Med Parasitol       Date:  2011-06

6.  Topographic congruence of calcified parenchymal neurocysticercosis and other structural brain lesions with epileptiform activity.

Authors:  Erin K Saito; Meera Nagpal; Amanda Leon; Bijal Mehta; Aaron Matthew McMurtray
Journal:  Trop Parasitol       Date:  2016 Jan-Jun
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.